Chronic AntiBody-Mediated Rejection (cABMR) is the leading cause of late kidney transplant loss (after 1 year of kidney transplantation). Its therapeutic management is poorly codified and there is currently no treatment referring. Extracorporeal phototherapy (ECP) is a therapeutic apheresis that involves purifying mononucleated cells in the blood, exposing them to UltraViolet A (UVA) and re-injecting them to the patient. This treatment is used as common care in the first line as part of the treatment of cutaneous T lymphoma and in the second line as part of the graft versus host reaction after bone marrow allograft. The mechanisms underlying the action of the ECP are not well known. They are mediated by the reinjection of cells exposed to UVA which enter apoptosis and induce immunomodulation. Recent work during cABMR shows that TFH lymphocytes, the maturing population of B lymphocytes, are deregulated and activated. The hypothesis is that ECP can modulate T Follicular Helper (TFH) lymphocytes during cABMR.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
30
The principle of ECP is to collect mononucleated cells from the blood by centrifugation. After purification, the mononucleated cells are incubated ex-vivo with a photo-activatable DNA intercalating agent (8-methoxypsoralen, UVADEX®), then re-injected to the patient.
Chu Besancon
Besançon, France
RECRUITINGCHU Clermont Ferrand
Clermont-Ferrand, France
RECRUITINGChu Saint Etienne
Saint-Etienne, France
RECRUITINGCHU de STRASBOURG
Strasbourg, France
RECRUITINGFrequency of TFH cells and their activation markers
Variation in the frequency of TFH cells and their activation markers under treatment.
Time frame: From the 1st session of ECP to 1 year after the 1st session
Subsequent ECP response in patients with cABMR
Study of the 3-month TFH/TFR value of ECP treatment as a marker for subsequent ECP response in patients with cABMR
Time frame: 3 months of treatment per ECP
Concentration of pro and anti-inflammatory cytokines
Study of the concentration of pro-inflammatory cytokines (IL-6, TNFα, IL-1β, IL-17, IFN-gamma, IL-21, IL-12, IL-17, CXCL13) and anti-inflammatory cytokines (IL10, TGF-b) over time in ECP
Time frame: From the 1st session of ECP to 1 year after the 1st session
Concentration of circulating B-cell populations
Study of the concentration of circulating B-cell populations due to ECP
Time frame: From the 1st session of ECP to 1 year after the 1st session
Measurement of genetic markers in TFH cells
Study of genetic markers in TFH cells in cell co-culture in vitro to describe their function
Time frame: At 1 week of the 1st session of ECP and at 3 month after the 1st session
Comparison of clinical data of patients
Clinical measures (medical examinations) of patients
Time frame: From the 1st session of ECP to 1 year after the 1st session
Comparison of biological data of patients
Biological measures (blood samples) of patients
Time frame: From the 1st session of ECP to 1 year after the 1st session
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.